Genome instability is an enabling characteristic of cancer that facilitates the acquisition of oncogenic mutations that drive tumorigenesis. Underlying much of the instability in cancer is DNA replication stress, which causes both chromosome structural changes and single base-pair mutations. Common fragile sites are some of the earliest and most frequently altered loci in tumors.
| GENOMIC INSTABILITY IN CANCER
One of the striking features of cancer cells is their highly abnormal genomes. 1 From changes in chromosome ploidy, to inter-chromosome translocations, large deletions and amplifications of chromosomal regions, to smaller insertions and deletions, and thousands of point mutations at the single nucleotide level, cancer genomes are highlymutated. 2 Many mutations accumulate gradually over the evolution of tumors, and others occur simultaneously in a single catastrophic event. [3] [4] [5] What causes cancer genomes to become so unstable? In familial cancer syndromes, often genome instability arises due to germline mutation in a DNA repair factor that performs an important genome caretaker function. 6 However, the known DNA caretakers are rarely inactivated in sporadic cancers, suggesting initiation of genome instability by another mechanism(s). 7 One hypothesis states that DNA replication stress, a term encompassing a variety of challenges to replication fork progression, 8 underlies cancer genome instability. 7, [9] [10] [11] Indeed, cancer genomes exhibit tell-tale signs of replication stress including the frequent deletions and amplifications that occur in certain genomic loci known as the common fragile sites (CFSs). [12] [13] [14] [15] [16] [17] CFSs are large chromosomal regions that are very sensitive to replication stress-inducing agents, such as the DNA polymerase inhibitor aphidicolin. 18 Thus, the observation that CFSs are frequently altered in cancer suggests replication stress is a common feature of cancer cell proliferation. 17 Numerous models have been proposed to explain their sensitivity to replication stress, 19, 20 and at least for several of the most "fragile" CFSs, it appears replication stress prevents the completion of DNA replication in these regions before the onset of mitosis. 19 CFSs are late-replicating regions and often overlap with large genes. 21, 22 They can be cell-type specific, likely owing to the difference in chromatin architecture and replication timing among different cell or tissue types. 19, 22 For example, CFS FRA3B, located at 3p14.2, is late replicating and extremely fragile in lymphocytic cells but less so in fibroblast cell lines. 23 Among the CFSs, FRA3B, and FRA16D loci exhibit the greatest fragility in cells originating from hematopoetic and epithelial tissues. 21 In cancer cells, the FRA3B locus is one of the most commonly deleted regions with alterations occurring in more than 50% of cancers and at the earliest, precancerous stages of tumorigenesis. 24 Because cancer cells are subjected to heightened levels of replication stress, it is a common view that the frequent deletions at FRA3B are passenger alterations that do not directly influence cancer development. 15 However, FRA3B overlaps with the fragile histidine triad (FHIT) gene, and numerous studies have demonstrated that FHIT encodes a tumor suppressor. 25 Accordingly, the corresponding loss of FHIT protein following FRA3B deletion is a major contributor to and predictor of the formation of malignant cancers.
| THE FRAGILE HISTIDINE TRIAD PROTEIN
FHIT belongs to the histidine triad family and is an enzyme with in vitro diadenosine triphosphate (Ap3A) and diadenosine tetraphosphate (Ap4A) hydrolase activity. 26 FHIT cleaves these dinucleosides to form AMP and ADP. 26 Though the precise role of this chemical reaction remains unknown, mutant FHIT alleles with reduced Ap3A binding activity fail to suppress tumor formation in vitro and in vivo. 27, 28 Recent advances in our understanding of FHIT unveiled a somewhat surprising and perhaps ironic role, given the sensitivity of CFSs to replication stress: the ability of this tumor suppressor to prevent spontaneous replication stress. 29 The first evidence that FHIT prevented replication stress came from studies on the frequency of chromosome alterations in mouse ploid. 31 Moreover, continued proliferation following FHIT loss leads to large deletions and amplifications, particularly at known CFS loci. 31, 33, 45 Replication stress is known to induce micronucleus formation, aneuploidy, copy number changes, and deletions at CFS 11, [46] [47] [48] ; therefore, it is likely that many of these chromosomal alterations stem from the spontaneous replication stress induced by loss of FHIT.
As CFSs and the genes that span them are uniquely sensitive to replication stress, it is intriguing that FHIT itself suppresses spontaneous replication stress. In this way, FHIT helps to ensure its own integrity by minimizing the stress to which the FRA3B/FHIT locus is most sensitive. Indeed, in one report, FHIT-knockdown caused large deletions within the FRA3B/FHIT locus itself. 33 This raises an interesting question: how does evolution lead to preservation of such a function at a highly unstable locus? It seems more logical that evolution would select against an unstable locus encoding a genome caretaker function, yet the evidence in mice and human cells indicate it has been conserved in mammals. Moreover, another putative DNA caretaker, WWOX, is encoded at the other most fragile CFS, FRA16D.
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Thus, for unknown reasons, evolution may have allowed on more than 
| THE FHIT-DEFICIENT POINT MUTATION SIGNATURES
The discovery that FHIT prevents replication stress and genome instability raised the possibility that FHIT-loss may also induce somatic point mutations. Indeed, studies found that clusters of point mutations can arise simultaneously on long stretches of single-stranded DNA at stressed replication forks and resected DNA breaks, 52 Recently, it was shown that loss of FHIT mRNA expression across many cancer types is highly associated with the mutational signature 5 in those cancers, 61 a signature previously known only to be associated with age at diagnosis. It was concluded that FHIT expression loss is likely responsible for occurrence of signature 5. In support of this conclusion, the mutation profile of Fhit-knockout mouse cells and tissues, closely resembles signature 5 ( Figure 2) . 61, 62 Given that large fractions of leukemia, breast, lung, and gastric tumors, and many other FIGURE 2 Similarities in the fragile histidine triad (Fhit)-knockout mutation signature and cancer signature 5. The Fhit ko mouse kidney tissue total mutation profile was adapted from figure 3 of Paisie et al. 62 Human mutational signature 5 was adapted from Alexandrov et al. 63 cancer types have reduced or absent FHIT, 25 a mutation signature caused by FHIT-loss would be predicted to be ubiquitous in cancer, like signature 5. Of the four dNTPs, dTTP are uniquely synthesized in part through the activities of thymidylate synthase (TYMS) and thymidine kinase 1 (TK1). 64 Notably, FHIT-deficiency severely reduced TK1 protein levels. 31, 32 TK1 levels fluctuate with the cell cycle, peaking in S phase when dTTP biosynthesis occurs 64, 65 ; however, FHIT-deficient cells fail to accumulate TK1 in S phase, consistent with a decrease in dTTP levels. 66 FHIT increases ribosome abundance on TK1 mRNA and subsequent translation (Figure 3 ). 66 Moreover, FHIT promoted translation of a luciferase reporter harboring the 5 0 -untranslated region (UTR) of the TK1 mRNA, suggesting that FHIT directs ribosome binding to certain 5'-UTR structures (65) .
| MECHANISM OF THE GENOME CARETAKER FUNCTION OF FHIT
Precisely how FHIT increases translation of TK1 is unclear. FHIT itself does not appear to be an RNA-binding protein. 66 Instead, FHIT may promote translation through its dinucleoside binding activity, as
FHIT mutants with reduced dinucleoside-binding fail to increase TK1 expression and fail to prevent DNA break formation. 35, 66 As a dinucleoside triphosphate hydrolase, FHIT can cleave fluorescentlylabelled cap-like molecules, 67 and recent evidence implicates FHIT as a scavenger decapping enzyme (Figure 3) . 68 Scavenger decapping enzymes cleave the 5 0 cap from mRNAs that have undergone 3 0 -5 0 exonuclease degradation. 69 Thus, it was proposed that FHIT lowers intracellular cap-like molecules. 66 It is still unclear how this promotes TK1 translation, though an intriguing hypothesis is that cap-like molecules compete with certain capped mRNAs for eIF4E-binding, a critical step in translation (Figure 3) . 66 FHIT has several other reported tumor suppressor functions that do not involve its role in maintaining TK1 levels and dTTP pools. 25 Importantly, cancer initiation is associated with changes in 5'-UTR translation start sites. 70 Thus, it was proposed that FHIT modulates ribosome binding and translation of other mRNAs involved in cancer.
Ribosome profiling revealed that FHIT modulates ribosome-binding particularly at the 5'-UTR of a number of cancer-associated mRNAs, 71, 72 suggesting loss of FHIT in early cancer formation may drive the changes in translation observed in early cancer stages.
| CONSEQUENCE OF FHIT-LOSS-INDUCED INSTABILITY AND MUTATION
Tumorigenesis is driven by oncogenic mutations that activate or amplify oncogenes and inactivate or delete tumor suppressors. Such mutations promote the acquisition of the cancer hallmarks. 2 The presence of genome instability in cancer cells enables tumorigenesis by increasing the mutation frequency and consequently the frequency of oncogenic mutation. 73 Because loss of FHIT protein in precancerous cells initiates genome instability, it was proposed that FRA3B/FHIT deletions facilitate the process of transformation through increasing oncogenic mutations. 45 In support of this hypothesis, experiments using primary mouse embryonic fibroblasts (MEFs) from wild-type and
Fhit-null mice revealed that Fhit-loss triggered gains and losses at several different genomic loci. 31, 45 Notably, the Mdm2 gene was amplified and correlated with the acquisition of replicative immortality, a cancer hallmark characteristic. 31 Mdm2 amplifications, which consequently increase Mdm2 protein abundance, spontaneously transform primary mouse cells, through binding and inactivation of p53. 74 Normally, p53 enforces cellular senescence after a limited number of cell divisions by transactivating p21, which then binds to and inactivates cyclin-dependent kinases. 75 In primary murine kidney epithelial cells established from wild-type and Fhit-null mice, Fhit-deficiency led to
Trp53 (mouse homolog of TP53) mutations in the DNA-binding domain or a decrease in p53 protein levels. 45, 76 These changes correlated with a dramatic loss of p21 expression, a striking increase in clonogenicity, resistance to genotoxin-induced apoptosis and senescence, and increased tumorigenicity upon transplantation in mice. 45, 76 While these studies were correlative in nature, they are consistent with Fhit-loss-induced genome instability as a facilitator of mutational inactivation of p53 and tumorigenesis. More direct experimental evidence was obtained using transient knockdown of FHIT in human cells. FHIT knockdown increased APOBEC3B-mediated TP53 mutation. 32 Importantly, the increased frequency of mutation in FHIT-deficient cells was likely due to reduced TK1 translation, dNTP imbalance and elevated replication stress as thymidine supplementation prevented TP53 mutations. 32 The connection of FHIT-loss-induced genome instability and recurrent mutational inactivation of p53 in different models is fascinating for a number of reasons. First, deletions in FHIT and mutations in TP53 are the most frequent genetic alterations observed in cancer, and in many instances, co-mutation of both FHIT and TP53 occur more frequently than either one alone. The experimental evidence we described above suggests that the co-occurrence of FHIT loss and TP53 mutation may be causative due to the increased frequency of mutation following FHIT loss. Consistent with a causative explanation for their co-mutation, deletions at the FHIT locus and loss of FHIT protein happen in the earliest stages of tumorigenesis and precede TP53 mutation.
FHIT-loss may create a selective pressure for TP53 mutation or MDM2 amplification. This is because FHIT-loss induces DNA breaks and chromosome instability, both of which result in senescence or apoptosis of p53-proficient cells. Fhit-null mouse primary kidney cells with an intact p53 pathway express higher levels of p21 and have a reduced colony-formation capacity compared to their wild-type counterparts. 45 Importantly, after 10-12 passages in culture, Fhit-null cells spontaneously acquire Trp53 mutations, loss of p21 expression, and a striking increase in clonogenicity. 45 Such observations are consistent with FHIT-loss creating a selective pressure for TP53 mutation and provide an explanation for the frequent alterations at both genetic loci in cancer. 
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